Quantitation of the density of cell surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA

Journal of Immunological Methods

Volumn 197, Issue 1-2, 1996, Pages 51-67

  Ravindranath, Mepur H ^a   Bauer, Philip M ^a   Cornillez Ty, Cromwell ^a   Garcia, Janet ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

carbohydrate epitope; cell suspension; cryopreservation; ELISA; flow cytometry; G(D2); G(D3); ganglioside; tumor associated carbohydrate

Indexed keywords

CARBOHYDRATE; EPITOPE; GANGLIOSIDE GD3; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ARTICLE; CANCER; CANCER IMMUNOTHERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; TUMOR BIOPSY;

EID: 0030590645     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/0022-1759(96)00128-7     Document Type: Article

References (54)

1. Brennan, J., Takei, F. and Wong, S. and Mager, D.L. (1995) Carbohydrate recognition by a natural killer cell receptor, Ly-49C. J. Biol. Chem. 270, 9691
2. Burger, M.M. (1970) Restoration of normal growth by covering of agglutinin sites on tumor cell surface. Nature 228, 512.
3. D3 antigen. J. Immunol. 145, 891.
4. D3 in adhesion plaques and on the surface of human melanoma cells. Proc. Natl. Acad. Sci. USA 81, 5767.
5. D3 on human melanoma serves as a relevant target antigen for monoclonal antibody mediated tumor cytolysis. Proc. Natl. Acad. Sci. USA 82, 5155.
6. D3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J. Cell Biol. 102, 688.
7. D2 monoclonal antibody in the diagnosis and therapy of human neuroblastoma. Prog. Clin. Biol. Res. 27, 595.
8. 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J. Clin. Oncol. 5, 1430.
9. Di Tommaso, A., De Magistris, M.T., Bugnoli, M., Marsili, I., Rappuoli, R. and Abrignani, S. (1994) Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing. Infect. Immun. 62, 1830.
10. Fredman, P. (1994) Gangliosides associated with primary brain tumors and their expression in cell lines established from these tumors. Progr. Brain Res. 101, 225.
11. Grayson, G. and Ladisch, S. (1992) Immunosuppression by human gangliosides II. carbohydrate structure and inhibition of human NK activity. Cell. Immunol. 139, 18.
12. Hakomori, S.-I. (1973) Glycolipids of tumor cell membrane. Adv. Cancer Res. 18, 265.
13. Hakomori, S.I., Teather, C. and Andrews, H. (1968) Organizational difference of cell surface 'hematoside' in normal and virally transformed cells. Biochem. Biophys. Res. Commun. 33, 563.
14. Huang, P., Dong. A. and Caughey W.S. (1995) Effects of dimethyl sulfoxide, glycerol, and ethylene glycol on secondary structures of cytochrome c and lysozyme as observed by infrared spectroscopy. J. Pharm. Sci. 84, 387.
15. D3 gangliosides. J. Natl. Cancer Inst. 81, 440.
16. D2. Proc. Natl. Acad. Sci. USA 83, 8694.
17. Irie, R.F., Matsuki, T. and Morton, D.L. (1989) Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1, 786.
18. Irie, R.F. and Ravindranath, M.H. (1990) Gangliosides as targets for monoclonal antibody therapy of cancer. In: C.A.K. Borrebaeck and J.W. Larrick (Eds.), Therapeutic Monoclonal Antibodies. Stockton Press, New York, pp. 75-94.
19. Kyriakos, R., Shih, L.B., Ong, G.L., Patel, K., Goldenberg, D.M. and Mattes, M.J. (1992) The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res. 52, 835.
20. Ladisch, S. (1987) Tumor cell gangliosides. Adv. Pediatr. 34, 45.
21. Ledeen, R.W. and Yu, R.K. (1982) Gangliosides: Structure, isolation and analysis. Methods Enzymol. 83, 139.
22. Livingston, P.O. (1995) Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol. Rev. 145, 147.
23. Lloyd, K.O., Gordon, C.M., Thampoe, I.J. and DiBenedetto, C. (1992) Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells. Cancer Res. 52, 4948.
24. 2+. Glycoconj. J. 11, 97.
25. Matzku, S., Brocker, E.B., Bruggen, J., Dippold, W.G. and Tilgen, W. (1986) Modes of binding and internalization of monoclonal antibodies to human melanoma cell lines. Cancer Res. 46, 3848.
26. McCoy, J.P., Jr. and Chambers, W.H. (1991) Carbohydrates in the functions of natural killer cells. Glycobiology 1, 321.
27. Morgan, A.C. and McIntyre, R.F. (1983) Monoclonal antibodies to human melanoma-associated antigens: An amplified enzyme-linked immunosorbent assay for the detection of antigen, antibody and immune complexes. Cancer Res. 43, 3155.
28. Morton, D.L., Foshag, L.J., Nizze, A.J., Famatiga, E., Hoon, D.S.B. and Irie, R.F. (1989) Active specific immunotherapy in malignant melanoma. Semin. Surg. Oncol. 5, 420.
29. Morton, D.L., Foshag, L.J., Hoon, D.S.B., Nizze, A., Famatiga, E., Wanek, L.A., Chang, C., Davtyan, D.G., Gupta, R.G., Elashoff, R. and Irie, R.F. (1992) Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216, 463.
30. Natali, P.G., Fawwaz, R., Ruiter, D.J., Bigotti, A., Kageshita, T., Temponi, M. and Ferrone, S. (1989) Immunodiagnostic and immunotherapeutic applications of antihuman melanoma associated antigen monoclonal antibodies. In: C.J. Conti et al. (Eds.), Skin Tumors: Experimental and Clinical Aspects. Raven Press, New York, pp. 133-163.
31. M3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. J. Immunol. 139, 3171.
32. 4) cf human colonic adenocarcinoma and the monoclonal antibody (FH7) defining this structure. J. Biol. Chem. 261, 5487.
33. Oettgen, H.F. (1989) Gangliosides and Cancer. VCH Publishers, New York, pp. 366.
34. Peters, L.C. and Hanna, Jr., M.G. (1980) Active specific immunotherapy of established metastasis: Effect of cryopreservation procedures on tumor cell immunogenicity in guinea pigs. J. Natl. Cancer Inst. 64, 1521.
35. Portoukalian, J., Zwinglestein, G., Dore, J.F. and Bourgoin, J.J. (1976) Studies of a ganglioside fraction extracted from human malignant melanoma. Biochimie 58, 1285.
36. Pukel, C.S., Lloyd, K.O., Travassos, L.R., Dippold, W.G., Oettger, H.F. and Old, L.J. (1982) GD3, a prominent ganglioside of human melanoma: Detection and characterization of mouse monoclonal antibody. J. Exp. Med. 155, 1133.
37. Ravindranath, M.H. and Morton, D.L. (1991) Role of gangliosides in active immunotherapy with melanoma vaccine. Int. Rev. Immunol. 7, 303.
38. D3 is recognized by Cancer antennarius lectin. J. Biol. Chem. 263, 2079.
39. Ravindranath, M.H., Ravindranath, R.M.H., Morton, D.L. and Graves, M.C. (1994) Factors affecting the fine specificity and sensitivity of serum antiganglioside antibodies in ELISA. J. Immunol. Methods 169, 257.
40. D3 ratio as an index for the maragement of melanoma. Cancer 67, 3029.
41. D2, antibodies for cancer immunotherapy. Prog. Brain Res. 101, 201.
42. Reisfeld, R.A. and Schrappe, M. (1990) Current status and future perspectives of chemoimmunoconjugates for the treatment of cancer. In: C.A.K. Borrebaeck and J.W. Larrick (Eds.), Therapeutic Monoclonal Antibodies. Stockton Press, New York, pp. 57-73.
43. Sonnino, S., Ghidoni, R., Marchesini, S. and Tettamanti, G. (1979) Cytosolic gangliosides: occurrence in calf brain as ganglioside-protein complexes. J. Neurochem. 33, 117.
44. Steplewski, Z., Spira, G., Blaszczyk, M., Lubeck, M.D., Radbruch, A., Illges, H., Herlyn, D., Rajewsky, K. and Scharff, M. (1985) Isolation and characterization of anti-monosialo-ganglioside monoclonal antibody 19.9 class-switch variants. Proc. Natl. Acad. Sci. USA 82, 8653.
45. D3. Arch. Biochem. Biophys. 261, 51.
46. Takahashi, K., Ono, K., Hirabayashi, Y. and Taniguchi, M. (1988) Escape mechanisms of melanoma from immune system by soluble melanoma antigen. J. Immunol. 140, 3244.
47. Taniguchi, M. and Wakabayashi, S. (1984) Shared antigenic determinant expressed on various mammalian melanoma cells. Gann 75, 418.
48. Tettamanti, G. and Riboni, L. (1994) Ganglioside turnover and neural cells function: a new perspective. Progr. Brain Res. 101, 77.
49. Trinchera, M. and Ghidoni, R. (1989) The glycosphingolipid sialyltransferases are located in different sub-Golgi compartments in rat liver. J. Biol. Chem. 264, 15766.
50. Urdal, D.L. and Hakomori, S.I. (1983) Characterization of tumor-associated ganglio-n-triaosylceramide in mouse lymphoma and the dependency of its exposure and antigenicity on the sialosyl residues of a second glycoconjugate. J. Biol. Chem. 258, 6869.
51. D3 ganglioside in patients with melanoma: Induction of inflammatory responses at tumor sites. J. Clin. Oncol. 6, 1636.
52. Welt, S., Carswell, E.A., Vogel, C.W., Oettgen, H.F. and Old, L.J. (1987) Immune and non-immune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialo-ganglioside GD3 on the surface of melanoma cells. Clin. Immunol. Immunopathol. 45, 214.
53. Werkmeister, J.A., Triglia, T., Mackay, I.R., Dowling, J.P., Variogos, G.A., Morstyn, G. and Burns, G.F. (1987) Fluctuations in the expression of a glycolipid antigen associated with differentiation of melanoma cells monitored by a monoclonal antibody Leo Mel 3.1. Cancer Res. 47, 225.
54. D3 ganglioside by mouse monoclonal antibodies. Proc. Am. Assoc. Cancer Res. 37, 459.